Bio-Techne Corp. closed 31.67% below its 52-week high of $85.57, which the company reached on May 15th. The stock underperformed when compared to some of its competitors Tuesday, ...
13 小时
Zacks Investment Research on MSNBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Tevogen Bio (NASDAQ:TVGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a ...
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD ...
Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...
Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...
Since the announcement, BIO stock has lost 9.5% to $277.16 last Friday. The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical ...
Mustang Bio (NASDAQ:MBIO) stock plunged 29% post-market after the company announced it has exited the lease for its manufacturing facility in Worcester, Mass. and relocated its headquarters to ...
The figure missed the Zacks Consensus Estimate marginally by 0.2%. Following the earnings announcement, BIO stock declined 0.4% in yesterday’s after-market trading. Revenues of $667.5 million ...
24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ ... The congress will take place at the Roma Conventi As major U.S. stock indexes face potential weekly losses following a disappointing ...
Gossamer Bio develops Seralutinib ... potentially prove that its PVR reduction is competitive. In my view, the stock is basically a binary bet on Seralutinib, which will give us top-line data ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果